GenSight Biologics announces the first results from new meta-analyses on the improvement in vision achieved with Lumevoq® gene therapy in patients with Leber's hereditary optic neuropathy (NOHL).

These results show that patients treated with Lumevoq ® gene therapy (GS010; lenadogene nolparvovec) had a higher rate of visual recovery than patients treated with idebenone and untreated patients (natural course).

This is the first set of meta-analyses to compare visual outcomes in patients with Leber's hereditary optic neuropathy (NOHL) with ND4 mutation only.

Dr. Nancy J. Newman, LeoDelle Jolley Chair and Professor of Ophthalmology and Neurology at Emory University School of Medicine in Atlanta, USA, presented the results at NANOS 2024. She said, ' This study is very important in order to compare the results of these therapies in achieving equivalent endpoints. It is clear that the degree of efficacy of gene therapy was superior to that of the other options currently available, i.e. no treatment and the use of idebenone, as previously administered in studies. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.